Clinical trial NCT02309723: Influence of Beta Amyloid Imaging on Care of Patients Cognitive Complaints.
Official title: A Survey of Clinicians to Assess the Influence of Beta-amyloid Imagining Information on the Diagnosis and Management of Hypothetical Patients With Cognitive Complaints
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Alzheimer's Disease
Mild Cognitive Impairment
Keywords: Alzheimer's Disease
Mild Cognitive Impairment
Neuroimaging
Diagnostic Tool
Lead sponsor: Tufts Medical Center
Sponsor class: OTHER
Collaborators: name: GE Healthcare
First posted: 2014-12-05
Enrollment: 315
Sex: ALL
Minimum age (years): 18
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: When older patients develop cognitive problems - like memory loss - there may be any of several underlying causes, sometimes occurring in combination. Clinicians have a better chance of providing appropriate treatment if they understand what the cause of the problem is. A diagnostic tool can help the patient by helping the clinician to make a more accurate diagnosis. This study investigates whether a new diagnostic tool - beta amyloid imaging - may potentially improve medical practice. The tool can potentially improve practice only if it can influence clinical judgment. This study investigates whether the provision of beta amyloid imaging information influences clinical judgment. The investigators will conduct a survey that presents clinicians with descriptions of hypothetical older patients with cognitive complaints. Some of the respondents also receive beta amyloid imaging information. The investigators will test the investigators hypothesis that the information will affect diagnostic judgment and management recommendations by comparing the responses of clinicians who receive the beta amyloid information to the responses of clinicians who do not.


Eligibility criteria: Inclusion Criteria:

* Practicing clinicians describing their training and practice as any of the following: neurologist, geriatrician, psychiatrist.
* Included respondents must also attest that they are a physician who is experienced in the assessment and diagnosis of dementia.

Primary outcomes:
measure: Influence of the Neuroimaging Test on a Finding of Alzheimer's Disease as the Underlying Cause of the Mild Memory Loss
timeFrame: Online Survey - completion during the estimated 2-3 month field period
measure: Likelihood of Recommending a Medication Indicated for Alzheimer's Disease
timeFrame: Online Survey - completion during the estimated 2-3 month field period
measure: Likelihood of Recommending That Spouse Take Various Cognitive Deficit Disease Management Measures
timeFrame: Online Survey - completion during the estimated 2-3 month field period
Secondary outcomes:
Other outcomes:
Locations:
city: Boston
country: United States
facility: Tufts Medical Center
state: Massachusetts
Study officials:
affiliation: Tufts Medical Center
name: Joshua T. Cohen, Ph.D
role: STUDY_DIRECTOR
affiliation: Tufts Medical Center
name: Peter J Neumann, ScD
role: PRINCIPAL_INVESTIGATOR
References: